Gamma Biosciences, a life sciences tools platform created by KKR, announced that it has acquired Nanopareil, a US-based company developing next-generation nanofiber membrane products for chromatographic separation in bioproduction.
Nanopareil’s membrane technology employs a novel, durable nanofiber structure that offers significant performance advantages compared with conventional chromatography resins as well as similar, non-resin-based separation technologies.
Gamma will operate Nanopareil as part of its existing subsidiary, Astrea Bioseparations. Together with Astrea’s recent acquisition of Essential Life Solutions, the US-based developer of SNAP brand chromatography columns and other accessories, Nanopareil positions Astrea as a leader in next-generation, downstream purification for biopharmaceuticals and advanced therapies.
Speaking on the acquisition, Matt Gunnison, President of Gamma Biosciences, said, “We are excited to bring Nanopareil into the Gamma family as part of Astrea. Nanopareil’s highly innovative technology and deep expertise in the field of bioseparations supports our commitment to help our customers achieve new levels of process efficiency and performance.”
Dr Steve Burton, CEO of Astrea Bioseparations, added, “Nanopareil’s robust and highly porous nanofiber membrane provides significant performance advantages in comparison to beaded chromatography media and competing non-woven membranes, including very high surface area and binding capacities, as well as pore sizes compatible with today’s larger advanced therapies. With almost instantaneous binding and residence times in the region of one second, Nanopareil brings a combination of features that addresses key challenges currently faced by the biomanufacturing industry.”
“We are equally excited to be joining the growing team of world-class professionals at Gamma Biosciences and Astrea,” said Dr. Todd Menkhaus, Co-Founder and CSTO of Nanopareil LLC. “We look forward to our collaboration that will bring forward Nanopareil’s technology to dramatically improve downstream purification operations for biopharmaceuticals”
“From our first meeting, we quickly developed an extraordinary partnership with Astrea,” said Craig Arnold, CEO of Nanopareil LLC. “The Astrea team has a strong track record of bringing innovative new products to the market. With their leadership and capabilities, Nanopareil will be well positioned to become the next-generation market leader.”
Nanopareil was advised in the transaction by John Chickosky of Binder Associates, GmbH.
Created by KKR, Gamma’s mission is to build a leading player in next-generation bioprocessing for advanced therapies by acquiring high-potential businesses with outstanding technology and accelerating their growth.
–AN
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.